Gregory W. Roloff, MD, on Assessing Real-World Experience of Brexu-Cel in Adults With B-ALL


The chief hematology/oncology fellow at University of Chicago discussed new data from the ROCCA collaborative study presented at ASH 2023.

“Adult patients with acute lymphoblastic leukemia have experienced improved outcomes in recent years but relapse is still a very common occurrence. Even now we have newer agents...immune based therapies, that had really revolutionized the care of these patients, but relapse is still a problem and the duration of remission that those new therapies provide is not as long as we would hope it to be.”

Adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with commercial brexucabtagene autoleucel (Tecartus; Kite) across US sites had a 90% complete response rate and 82% minimal residual disease negativity rate, according to the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) study. Investigators saw low rates of severe cytokine release syndrome but a 32% rate of grade 3-4 immune effector cell-associated neurotoxicity syndrome.

The new data from ROCCA were presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California, by Gregory Roloff, MD, chief hematology/oncology fellow, University of Chicago.

CGTLive spoke with Roloff to learn more about the background of the ROCCA study. He discussed the 2021 approval of brexu-cel and how it changed the treatment landscape but emphasized the need to understand the real-world experience of patients receiving, orattempting to receive the chimeric antigen receptor (CAR) T-cell therapy.

Roloff GW, Aldoss I, Kopmar NE, et al. Brexucabtagene autoleucel in adults with relapsed/refractory B-cell ALL: Outcomes and novel insights from the real-world outcomes collaborative of CAR T in adult ALL (ROCCA). Presented at:ASH 2023 Annual Meeting & Exposition. December 9-12; San Diego, CA. Abstract 1030
Recent Videos
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Stephanie Tagliatela on Researching AAV for Lennox-Gastaut, Alzheimer Disease, SCN9a Pain
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
© 2024 MJH Life Sciences

All rights reserved.